Jazeta Novum

Sitagliptin phosphate monohydrate, the active ingredient in Jazeta Novum, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and other antidiabetic agents are insufficient.

GNH USA supplies Jazeta Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured distribution channels across Europe, Asia, Africa and the Americas and meeting local regulatory requirements.

Jazeta Novum, a DPP‑4 inhibitor, is used in the management of type 2 diabetes mellitus.

- Monotherapy for type 2 diabetes mellitus: reduces HbA1c as a single agent. - Combination with metformin: provides additional glucose lowering when metformin alone is insufficient. - Combination with insulin: helps achieve glycemic targets in patients requiring insulin therapy.

Adverse reactions may occur with any medication and should be monitored by the prescribing clinician.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Nausea: occasional mild nausea, often transient. - Diarrhea: loose stools, usually self‑limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Joint pain: unexplained arthralgia that may be disabling. - Hepatic enzyme elevation: significant increase in liver transaminases.

Prior to initiating therapy, clinicians should evaluate patient‑specific factors and monitor for known risks.

- Renal function: assess baseline creatinine clearance and adjust therapy as needed. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Pancreatitis: advise patients to report persistent, severe abdominal pain. - Cardiovascular disease: use with caution in patients with a history of heart failure. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Sitagliptin may interact with other medicines; some combinations require avoidance while others need close monitoring.

Major Interactions (Avoid): - Insulin: increased risk of hypoglycemia when used together. - Sulfonylureas: additive hypoglycemic effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor renal function and electrolytes. - Diuretics: watch for changes in blood pressure and electrolytes. - Rifampin: may reduce sitagliptin exposure, potentially decreasing efficacy.